Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Konkuk University, Korea.
Am J Rhinol Allergy. 2011 Jul-Aug;25(4):e156-9. doi: 10.2500/ajra.2011.25.3646.
The MAST-CLA system (Hitachi Chemical Diagnostics, Inc., Mountain View, CA) is an in vitro diagnostic test for the simultaneous determination of specific IgE to different allergens. Recently, a new generation of MAST-CLA was developed (OPTIGEN; Hitachi Chemical Diagnostics). The purpose of this study was to determine the performance of these two tests for the diagnosis of allergic rhinitis.
Suspicious allergic rhinitis patients were divided into four groups and their medical records were reviewed: group 1 patients were tested with the MAST-CLA and skin-prick tests (251 patients), group 2 patients were tested with the OPTIGEN and skin-prick tests (319 patients), group 3 patients were tested with the MAST-CLA and CAP (104 patients) tests, and group 4 patients were tested with the OPTIGEN and CAP tests (270 patients). The correlation between MAST-CLA and OPTIGEN to skin-prick and CAP tests was determined.
The positivity percentage of MAST-CLA results was higher than with skin-prick and CAP tests, and the results for the OPTIGEN test were comparable with skin-prick test and CAP. This suggests that the MAST-CLA test might have a slightly higher rate of giving false positive results. The OPTIGEN test correlated better with the skin-prick test and CAP.
The OPTIGEN test performed better than the MAST-CLA test for diagnosing allergic rhinitis.
MAST-CLA 系统（日立化学诊断公司，加利福尼亚州山景城）是一种用于同时测定不同过敏原特异性 IgE 的体外诊断测试。最近，开发了新一代的 MAST-CLA（OPTIGEN；日立化学诊断）。本研究的目的是确定这两种测试在过敏性鼻炎诊断中的性能。
将可疑过敏性鼻炎患者分为四组并回顾其病历：组 1 患者接受 MAST-CLA 和皮肤点刺测试（251 例），组 2 患者接受 OPTIGEN 和皮肤点刺测试（319 例），组 3 患者接受 MAST-CLA 和 CAP（104 例）测试，组 4 患者接受 OPTIGEN 和 CAP 测试（270 例）。确定 MAST-CLA 和 OPTIGEN 与皮肤点刺和 CAP 测试的相关性。
MAST-CLA 结果的阳性百分比高于皮肤点刺和 CAP 测试，而 OPTIGEN 测试的结果与皮肤点刺测试和 CAP 相当。这表明 MAST-CLA 测试可能具有稍高的假阳性率。OPTIGEN 测试与皮肤点刺测试和 CAP 相关性更好。
OPTIGEN 测试在诊断过敏性鼻炎方面优于 MAST-CLA 测试。
